Half-Dose Photodynamic Therapy as a Novel Treatment Protocol for Circumscribed Choroidal Hemangioma.

Life (Basel)

Ophthalmology Division, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv-Yafo 6234906, Israel.

Published: October 2022

We present a case series of four patients with circumscribed choroidal hemangioma (CCH) treated with half-dose PDT, proposing this as a novel treatment protocol. Four patients with CCH were included, and then evaluated using multimodal imaging, including optical coherence tomography (OCT), fluorescein angiography, indocyanine green angiography, fundus autofluorescence, and ultrasound following treatment with half-dose and full-fluence PDT. Following half-dose PDT, all patients showed significant shrinkage of the hemangioma, functional improvement, and decrease of intra- and sub-retinal fluid. All patients remained stable after a single PDT treatment, with a follow-up of up to 60 months. No side effects were shown. This is the first report showing long term efficacy of half-dose PDT treatment in cases with CCH. The outcomes from this pilot study are comparable with results using full dose PDT protocols and it can be considered as a viable treatment option for CCH during the ongoing global verteporfin shortage.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696376PMC
http://dx.doi.org/10.3390/life12111748DOI Listing

Publication Analysis

Top Keywords

half-dose pdt
12
novel treatment
8
treatment protocol
8
circumscribed choroidal
8
choroidal hemangioma
8
pdt treatment
8
treatment
6
pdt
6
half-dose
5
half-dose photodynamic
4

Similar Publications

Safety and Efficacy of Half-dose and Half-fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-analysis.

Am J Ophthalmol

November 2024

Department of Ophthalmology and Vision Sciences (M.M.P. and R.P.K.), University of Toronto, Toronto, Canada; John and Liz Tory Eye Centre (P.J.K., R.H.M., and R.P.K.), Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address:

Purpose: To investigate the comparative efficacy and safety of half-dose photodynamic therapy (PDT) and half-fluence PDT in the management of chronic central serous chorioretinopathy.

Design: Systematic review and meta-analysis.

Methods: A comprehensive literature search was conducted on Ovid MEDLINE, Embase, and the Cochrane Library, covering publications from January 2000 to March 2024.

View Article and Find Full Text PDF

Therapies for Central Serous Chorioretinopathy: A Report by the American Academy of Ophthalmology.

Ophthalmology

October 2024

Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Department of Ophthalmology, Truhlsen Eye Institute, University of Nebraska Medical Center, Omaha, Nebraska.

Purpose: To assess the safety and efficacy of the multiple therapeutic modalities for the treatment of central serous chorioretinopathy (CSCR).

Methods: A literature search of English-language studies in the PubMed database with no date restrictions was last conducted in May 2024. The combined searches yielded 612 citations, 31 of which were selected for full-text review and for inclusion in this assessment.

View Article and Find Full Text PDF

Introduction: Half-dose photodynamic therapy (HD-PDT) with verteporfin is the mainstay treatment in central serous chorioretinopathy (CSC). Since 2021, there is a worldwide shortage of verteporfin. This called for adjustments of daily practice.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates whether the thickness of anterior scleral substantia propria (ASSP) can predict responses to half-dose photodynamic therapy (PDT) in patients with central serous chorioretinopathy (CSCR) over a 3-month period.
  • Conducted in multiple hospitals in Italy and Switzerland, the research involved 109 Caucasian patients, focusing on clinical data and optical coherence tomography measurements to categorize different CSCR phenotypes and their ASSP thickness.
  • Results indicated that thicker ASSP is associated with complex CSCR and a higher likelihood of PDT non-responsiveness, emphasizing its potential role in understanding CSCR's severity and treatment outcomes.
View Article and Find Full Text PDF

Purpose: To compare the visual and anatomical results of navigated subthreshold micropulse laser (nSML) and photodynamic therapy (PDT) in the treatment of chronic central serous chorioretinopathy (CSCR).

Methods: Patients who underwent either half-dose PDT or nSML for the management of chronic CSCR were included in this study. Comprehensive ophthalmic examination, fundus autofluorescence, and spectral domain optical coherence tomography (SD-OCT) were performed at baseline and at 1-, 3-, and 6-month follow-up visits after nSML or PDT.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!